Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.

Risitano AM.

Immunobiology. 2012 Nov;217(11):1080-7. doi: 10.1016/j.imbio.2012.07.014. Review.

PMID:
22964233
2.
3.
4.

Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.

Luzzatto L, Gianfaldoni G.

Int J Hematol. 2006 Aug;84(2):104-12. Review.

PMID:
16926130
5.
6.

Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.

DeZern AE, Brodsky RA.

Hematol Oncol Clin North Am. 2015 Jun;29(3):479-94. doi: 10.1016/j.hoc.2015.01.005. Epub 2015 Mar 7. Review.

7.

[Eculizumab in paroxysmal nocturnal hemoglobinuria].

Socié G, Varoqueaux N, Peffault de Latour R.

Med Sci (Paris). 2009 Dec;25(12):1126-9. doi: 10.1051/medsci/200925121126. Review. French.

8.

Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.

Röth A, Dührsen U.

Eur J Haematol. 2011 Dec;87(6):473-9. doi: 10.1111/j.1600-0609.2011.01701.x. Review.

PMID:
21883481
9.

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L.

Nat Biotechnol. 2007 Nov;25(11):1256-64. Erratum in: Nat Biotechnol. 2007 Dec;25(12):1488.

PMID:
17989688
10.

Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria.

DeZern AE, Uknis M, Yuan X, Mukhina GL, Varela J, Saye J, Pu J, Brodsky RA.

Exp Hematol. 2014 Oct;42(10):857-61.e1. doi: 10.1016/j.exphem.2014.06.007. Epub 2014 Jul 14.

11.

Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.

Varela JC, Brodsky RA.

Expert Rev Clin Immunol. 2013 Nov;9(11):1113-24. doi: 10.1586/1744666X.2013.842896. Review.

PMID:
24168416
12.

Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.

Heitlinger E.

Blood Rev. 2013 Dec;27 Suppl 1:S1-6. doi: 10.1016/S0268-960X(13)00080-5. Review.

PMID:
24331206
13.

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.

Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ.

Blood. 2010 Mar 18;115(11):2283-91. doi: 10.1182/blood-2009-09-244285. Epub 2010 Jan 12.

14.

Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

Szer J, Hill A, Weitz IC.

Clin Adv Hematol Oncol. 2012 Nov;10(11 Suppl 21):1-16.

PMID:
23271156
15.

Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.

Hill A, Ridley SH, Esser D, Oldroyd RG, Cullen MJ, Kareclas P, Gallagher S, Smith GP, Richards SJ, White J, Smith RA, Hillmen P.

Blood. 2006 Mar 1;107(5):2131-7. Epub 2005 Dec 1.

16.

Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Wong EK, Kavanagh D.

Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20. Review.

PMID:
25468487
17.

The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.

Rosse WF, Hoffman S, Campbell M, Borowitz M, Moore JO, Parker CJ.

Br J Haematol. 1991 Sep;79(1):99-107.

PMID:
1716964
18.

Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.

Rother RP, Rollins SA, Mennone J, Chodera A, Fidel SA, Bessler M, Hillmen P, Squinto SP.

Blood. 1994 Oct 15;84(8):2604-11.

19.

Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

Packman CH, Rosenfeld SI, Jenkins DE Jr, Thiem PA, Leddy JP.

J Clin Invest. 1979 Aug;64(2):428-33.

20.

Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.

Singer AL, Locke JE, Stewart ZA, Lonze BE, Hamilton JP, Scudiere JR, Anders RA, Rother RP, Brodsky RA, Cameron AM.

Liver Transpl. 2009 May;15(5):540-3. doi: 10.1002/lt.21714.

Supplemental Content

Support Center